Naproxcinod

DB06682InvestigationalSmall molecule

Investigated for use/treatment in pain (acute or chronic), inflammatory disorders (unspecified), osteoarthritis, and arthritis and arthritic pain.

Chemical structure of Naproxcinod
Mechanism
Curator reviewed
Primary indication
Investigated for use/treatment in pain (acute or chronic), inflammatory disorders (unspecified), osteoarthritis, and arthritis and arthritic pain.Curator reviewed
Formula / weight
C18H21NO6 · 347.367 g/mol (avg)
Code names
AR-P900758XX · AZD-3582 · HCT-3012

Resolves to

Compound
UNIIV24GR4LI3ICAS163133-43-5ChEMBLCHEMBL2103831ChEBI76254KEGGD09568
Clinical / RWD
ATCM01AE18
Structure
InChIKeyAKFJWRDCWYYTIG-ZDUSSCGKSA-NSMILESCOC1=CC2=CC=C(C=C2C=C1)[C@H](C)C(=O)OCCCCO[N+]([O-])=O
Targets
P35354PTGS2P23219PTGS1

What you can answer from here — as of June 15, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
8Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1ATC codeIncluding every combination product, plus 8 drug categories
Sign in
4+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Naproxcinod, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In